Compare Gilead Sciences, Inc. (GILD) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $163.51B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.66. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| GILD | VNQI | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $50.76 |
52-Week Low | $108.22 | $43.26 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.70, up 0.79% with a bullish technical signal from moving averages. The ETF provides international real estate diversification with 682 holdings across 30+ countries, featuring a low 0.12% expense ratio and 4.6% dividend yield. Recent analysis highlights its cost advantage over competitors like RWX (0.59% fee) and recovery potential as global real estate transactions are projected to grow over 10% in 2026.
The outlook remains constructive given VNQI's valuation at 11.9x P/E and 0.9x P/B, though total returns have lagged domestic peers. Key risks include currency exposure, international regulatory changes, and interest rate sensitivity. For investors seeking global real estate diversification with low costs, VNQI offers compelling value despite performance headwinds versus U.S.-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
